CNC

Business Profile & Competitive Position

Centene Corporation operates in the Healthcare sector, specifically the Medical - Healthcare Plans industry. The company describes itself as the nation’s largest managed care company focused on underserved populations. It provides affordable, high-quality coverage through Medicaid, Medicare (Advantage, Prescription Drug Plans, and supplemental products), and commercial plans sold on the Health Insurance Marketplace. The business runs through local brands and local teams supported by national scale, connecting members to not only medical care but also supports such as food, housing, utilities, and transportation.

The numbers show a company with enormous scale but currently weak profitability. For 2025, total revenue was $194.8 billion, split 57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other. Operating cash flow was $5.1 billion. As of December 31, 2025, membership totaled 27.6 million, including 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Centene is the largest Medicaid insurer, the largest Marketplace insurer, and the largest stand-alone PDP provider in the United States.

Scale leadership is clear, yet the margin figures do not point to a durable competitive moat measured in returns. Net margin is -2.6% and ROE is -24.0%, meaning the company is currently earning negative returns on shareholders’ equity. The positive operating cash flow — $5.1 billion on $194.8 billion in revenue — shows the underlying business still moves cash, but the negative margin and ROE imply that market share has not recently translated into pricing power or cost advantages strong enough to produce reported profits.

Financial Posture

Centene currently carries a market capitalization of $31.8 billion and trades at a P/E of -6.2. The negative P/E is a consequence of the -2.6% net margin, not a low valuation in the classic value-investing sense. ROE of -24.0% reinforces that invested capital is not presently generating a positive return. A beta of 1.10 indicates the stock has been slightly more volatile than the broad market.

The other side of the ledger is scale and cash flow. Annual revenue of $194.8 billion and operating cash flow of $5.1 billion point to a business with massive premium and claims volume. At the current price of $64.43, the stock sits essentially on top of its 50-day exponential moving average of $63.28, and the RSI of 48.6 is near neutral. In short, the financial posture is that of a large managed care platform with strong cash generation but currently impaired reported earnings.

Strategic Priorities & Outlook

Centene’s most recent 10-K filing lays out several near-term operational priorities:

• Continue refining the Medicare footprint so it overlaps more closely with Medicaid operations, and expand Dual Eligible Special Needs Plan (D-SNP) offerings to drive long-term growth.
• Maintain enterprise-level focus on the D-SNP opportunity, including integrated products aligned with CMS requirements taking effect through 2030.
• Advocate for policies and legislation aimed at preserving affordable Medicaid and Marketplace coverage, as well as cost-effective, high-quality care for PDP members.
• Implement 2026 corrective Marketplace pricing actions in states covering 95% of Marketplace membership, and expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states.

The filing also notes that Centene signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses, a move that should simplify the portfolio. The strategic emphasis is on D-SNP integration, Marketplace pricing remediation, and off-exchange commercial expansion. The CMS alignment timeline running through 2030 means regulatory execution is a multi-year theme rather than a one-time event.

Macro & Geopolitical Exposure

As a Medical - Healthcare Plans company, Centene’s macro exposure is primarily U.S. healthcare policy, regulation, and reimbursement levels rather than commodities, currency, or overseas trade.

Medicaid funding, state budget decisions, Medicare Advantage rate announcements from CMS, and the stability of Affordable Care Act Marketplace subsidies all directly affect premium revenue and medical loss ratios. Rule changes around Medicaid eligibility redetermination, D-SNP integration requirements, and Medicare Part D benefit design can shift membership and margins quickly. Interest rates matter through investment income and reserve discounting, while broader medical-cost inflation, drug pricing policy, and provider contract disputes influence the spread between premiums collected and claims paid. Trade policy and foreign exchange are relatively minor for a domestic managed care business, but pharmaceutical supply-chain costs and healthcare labor pressure can flow through to medical expenses. Political and election-cycle uncertainty frequently amplifies volatility for Medicaid and Marketplace insurers.

Recent Developments

On August 17, 2026, Centene appeared in several headlines. Zacks published “Should Value Investors Buy Centene (CNC) Stock?” and “Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks” (zacks.com). The more significant corporate news came from Forbes and Reuters: Forbes reported that Health Insurer Centene’s Chief Financial Officer is stepping down, while Reuters reported that Centene named Chris Neczypor as its new CFO (forbes.com, reuters.com). The CFO transition is the item most likely to draw investor attention, because it arrives as the company is working through its 2026 Marketplace pricing remediation, D-SNP expansion, and the Magellan divestiture. Executive changes at the CFO level are typically watched closely for signals about capital allocation discipline and financial reporting consistency, though the news itself does not imply a strategic reversal.

Earnings Behavior & Post-Earnings Drift

Centene has put up a strong record against the published consensus. Over the last eight reported quarters, the company has beaten estimates seven times, an 88% beat rate, with an average earnings surprise of 63.1%. The average 5-day price move in the trading sessions after earnings across those quarters was +2.83%, classified as an upward post-earnings drift.

The most recent quarters show how volatile price reactions can be even after large beats:

• On July 28, 2026, Centene reported EPS of $2.51 versus an estimate of $1.09, a 130.3% surprise. The stock fell 3.27% the next day and rose just 0.25% over the following five sessions.
• On April 28, 2026, EPS came in at $3.37 against $2.23 estimated, a 51.1% beat. Shares jumped 8.9% the next day and 6.88% over the next five sessions.
• On February 6, 2026, Centene reported a loss of $1.19 per share versus an estimated loss of $1.22007, a 2.5% beat. The stock slipped 1.09% the next day but drifted 5.51% higher over the next five sessions.
• On October 29, 2025, EPS of $0.50 crushed an estimated loss of $0.14475, a 445.4% surprise. Despite the beat, the stock dropped 6.21% the next day and fell 1.34% over the following five sessions.

The takeaway is that beats are the norm, but the market’s real expectation can run above the visible consensus. A published beat does not guarantee a positive next-day move. Looking ahead, Centene is scheduled to report next on October 27, 2026 before the open, with a consensus EPS estimate of $0.07. The low official estimate relative to recent results sets up a possible gap between the published number and the unofficial consensus.

For the full institutional verdict on Centene — including detailed analyst ratings, forward estimates, and consensus breakdowns — explore the complete CNC research dashboard on our platform.